A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
MeSH terms: Arthritis; Arthritis, Rheumatoid
Intervention: tocilizumab
Intervention description: 162 mg subcutaneously weekly or every two weeks, 96 weeks
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 47.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This multicenter, open-label, single arm, long-term extension study will evaluate the safety
      and efficacy of RoActemra/Actemra (tocilizumab) in participants with moderate to severe
      rheumatoid arthritis who have completed the 97-week WA22762 or the 96-week NA25220 core
      study. Participants will receive RoActemra/Actemra 162 milligram (mg) subcutaneously weekly
      (for participants entering from WA22762) or every two weeks (for participants entering from
      NA25220) for 96 weeks, with telephone call follow-up visits at Weeks 100 and 104.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Adult participants, >/= 18 years of age

          -  Participants who have completed the 97-week WA22762 or 96-week NA25220 core study on
             subcutaneous or intravenous RoActemra/Actemra and based on the investigator's judgment
             may continue to benefit from RoActemra/Actemra treatment in this study investigating
             the subcutaneous formulation

          -  Oral corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS) up to the
             maximum recommended dose are permitted if on a stable dose regimen for >/= 4 weeks
             prior to baseline

          -  Permitted non-biological disease-modifying anti-rheumatic drugs (DMARDs) are allowed

          -  Receiving treatment on an outpatient basis

          -  Females of childbearing potential and males with female partners of childbearing
             potential must agree to use reliable means of contraception

        Exclusion Criteria:

          -  Participants who have prematurely withdrawn from the WA22762 or NA25220 core studies
             for any reason

          -  Previous treatment with any cell-depleting therapies, including investigational agents
             or approved therapies

          -  History of severe allergic or anaphylactic reactions to human, humanized or mural
             monoclonal antibodies

          -  Evidence of serious uncontrolled concomitant disease

          -  Current liver disease as determined by the principal investigator

          -  History of diverticulitis, diverticulosis requiring antibiotic treatment or chronic
             ulcerative lower gastrointestinal (GI) disease such as Crohn's disease, ulcerative
             colitis or other symptomatic lower GI conditions that might predispose to perforations

          -  Known active current or history of recurrent infections

          -  Any major episode of infection requiring hospitalization or treatment with intravenous
             (IV) antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior
             to screening

          -  Active tuberculosis requiring treatment within the previous 3 years

          -  Primary or secondary immunodeficiency (history of or currently active)

          -  Pregnant or breast feeding women

          -  Body weight > 150 kilogram (kg)

          -  Inadequate renal, hepatic or hematologic function

          -  Positive for hepatitis B or hepatitis C